Translating Variant-Selective, Pan-RAS, and Combination Innovations into Robust, Potent Therapies Delivering Meaningful Clinical Benefit Across RAS-Driven Tumors
RAS-targeted drug development has entered a pivotal new phase. Following major clinical momentum across KRAS-mutant cancers, including Roche's recent Phase III success with divarasib and encouraging data emerging from Revolution Medicines' RAS(ON) portfolio, RAS has become one of oncology's most competitive and fast-moving therapeutic frontiers. As developers advance next-generation inhibitors, pan-RAS strategies, novel modalities, and combination approaches in parallel, programmes are rapidly expanding beyond G12C into G12D, G12V, G13D, and multi-variant targeting. The challenge has now shifted from validating RAS as a target to delivering durable responses, overcoming resistance, and broadening patient benefit.
The 8th RAS-Targeted Drug Development Summit is the industry's only forum dedicated exclusively to translating RAS therapies from early discovery through clinical development. Bringing together leaders across biopharma, including Bristol Myers Squibb, Amgen, Revolution Medicines, Verastem, Incyte, Jacobio Pharmaceuticals and NCI, the meeting focuses on the topics shaping the next era of RAS drug development: pan-RAS and pan-KRAS inhibition, RAS(ON) targeting, resistance mechanisms, pathway-based combinations, precision patient selection, and strategies to translate breakthrough clinical data into meaningful patient outcomes.
Join senior RAS-focused experts to gain actionable insights on next-generation targeting strategies, innovative modalities, smarter combination design, and precision patient stratification, equipping you to advance more effective RAS therapies for broader patient populations.
As the field of RAS-targeted therapies continues to evolve rapidly, this meeting plays an important role in bringing together leaders across academia, biotech, and industry to exchange perspectives and align on the key scientific and clinical challenges ahead.
Ivana Sullivan, Clinical Research Medical Director, Amgen
The meeting provides a platform to discuss an aspect of cancer biology that has been challenging to address. Finally, we are seeing promising advancements that have the potential to transform patient outcomes across multiple difficult to treat cancers.
Mani Mohindru, Chief Executive Officer, Cardiff Oncology
Thought leaders in the field will convene into a focused forum aimed at removing current obstacles on the development and clinical uptake of RAS inhibitors, with the ultimate goal of improving durability of response and safety of RAS inhibitors, extending the life of patients further.
Federico Innocenti, Senior Director, Clinical Development, Solid Tumors, BeOne Medicines
Explore the Full Event Guide
- Get the full agenda at a glance – including session details and focus day content
- See the complete speaker faculty – all experts, titles, and organisations in one place
- Understand the key scientific themes - from next generation inhibitors, to panRAS approaches & novel modalities
- Preview who you’ll meet – attendee profiles, company types, and networking formats
- Explore partnership and registration options - including pricing, deadlines, discounts, and opportunities to showcase solutions
Sneak Peak Of What To Expect This Year
Accelerate More Durable Responses with Smarter RAS Combination Strategies
Deliver Next-Generation KRAS Therapies with Greater Efficacy & Tolerability
Expand Patient Reach with Innovative Modalities Beyond Small Molecules
Broaden Therapeutic Impact Through Pan-KRAS & Pan-RAS Targeting
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.